Core Viewpoint - The announcement highlights a strategic collaboration between Baiaosaitu-B (02315) and Yushibo Co., Ltd. to accelerate the development of bispecific antibody-drug conjugates (BsAD2C) through a structured evaluation mechanism [1][2] Group 1: Agreement Details - The agreement grants Yushibo a right to obtain global exclusive licenses for two BsADC projects from Baiaosaitu [1] - Baiaosaitu will receive an upfront payment for the option, and subsequent payments will include option exercise fees, development and regulatory milestone payments, commercialization milestone payments, and future product sales revenue sharing [1] Group 2: Collaboration Background - This agreement deepens the collaboration initiated earlier in the year, which focused on evaluating and screening bispecific antibodies and dual-load antibody-drug conjugate (ADC) candidates with therapeutic potential [1] - The combination of Baiaosaitu's RenLite fully human light chain antibody development platform and Yushibo's antibody-drug conjugate (AD2C) technology is seen as a promising technical pathway for the development of a new generation of BsAD2C [1] Group 3: Project Advancement - The collaboration aims to leverage the complementary strengths of both platforms to advance the design of next-generation ADC molecules, addressing limitations observed in traditional ADC projects [2] - The project team is steadily progressing through key evaluation milestones, with decisions based on ongoing research data and Yushibo's internal processes and option exercise criteria [2]

Group 1 - The core viewpoint of the article highlights that Baiaoshaitu-B (02315) experienced a significant intraday increase of nearly 10%, reaching a new high of 39.46 HKD, and is currently trading at 38.72 HKD with a transaction volume of 17.64 million HKD [1] - On January 9, Baiaoshaitu announced a licensing agreement with Yushibo to systematically evaluate the BsADC project through a structured assessment mechanism, aiming to accelerate the development of the BsAD2C [1] - The agreement grants Yushibo an option for global exclusive licensing of two BsADC projects from Baiaoshaitu, which will also receive an upfront payment and subsequent payments upon the exercise of the option, including milestone payments and revenue sharing [1] Group 2 - According to a recent report by Cinda Securities, Baiaoshaitu's sales of model animals and preclinical pharmacological evaluation business are developing synergistically and are currently in a high growth phase [1] - Compared to industry peers, Baiaoshaitu's business model is relatively unique, focusing on high-margin humanized mouse strains and not offering low-margin standard strains, leading to high utilization of cage resources and the capability to expand internationally [1]